stockrow
Friday 6 November 2026
Export PCRX’s income statement to Excel — free account
Pacira BioSciences, Inc.
PCRX Healthcare Drug Manufacturers Specialty & Generic
Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024.
- Revenue
- −1.59%
- EPS
- +500.0%
- Free cash flow
- −18.5%
- Total debt
- −37.4%
Quarter to September 2026, against a year earlier
36.44
0.04
+0.11%
Follow PCRX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
0.96% | 0.71% | 2.05% | 5.24% | |
Piotroski F-Score |
8 | 8 | 8 | — | |
| 0.50% | 0.37% | 1.05% | 3.02% | ||
ROIC |
1.45% | 1.84% | 1.58% | 5.37% | |
Return on Tangible Assets |
1.24% | 0.95% | 2.35% | 6.36% | |
Average Days of Receivables |
62.34 | 62.40 | 64.78 | 60.35 | |
Free Cash Flow per Share |
3.07 | 3.28 | 4.55 | 4.24 | |
Free Cash Flow |
136.66 | 132.71 | 179.52 | 169.00 | |
Capital Expenditures |
(15.33) | (9.51) | (8.15) | (7.90) | |
| Other line items | |||||
Cash ROIC |
10.48% | 10.84% | 13.96% | 16.77% | |
Accounts Receivable Turnover |
6.12 | 6.38 | 6.05 | 6.24 | |
Accounts Payable Turnover |
8.74 | 8.17 | 6.51 | 0.00 | |
Inventory Turnover |
1.08 | 1.07 | 1.10 | 0.00 | |
Average Days of Payables |
36.93 | 33.68 | 41.19 | 0.00 | |
Days of Inventory on Hand |
372.59 | 361.43 | 316.59 | 0.00 | |
Tax Rate |
(0.58) | (0.61) | (0.17) | 0.02 | |
Research and Development Expense of Revenue |
16.15% | 16.34% | 16.36% | 16.52% | |
Selling, General and Administrative Expense of Revenue |
50.76% | 51.16% | 50.81% | 49.94% | |
Share Based Compensation of Revenue |
7.92% | 7.69% | 7.50% | 7.24% | |
Interest Coverage |
1.10 | 1.46 | 1.28 | 2.54 | |
Operating CF/Net income |
21.61 | 27.68 | 12.82 | 4.69 | |
Depreciation/Fixed assets |
0.63 | 0.66 | 0.64 | 0.00 | |
Capex/Depreciation |
(0.17) | (0.11) | (0.10) | 0.00 | |
Revenue per Share |
16.30 | 18.16 | 18.91 | 18.65 | |
Operating CF per Share |
3.41 | 3.51 | 4.76 | 4.44 | |
Capex per Share |
(0.34) | (0.23) | (0.21) | (0.20) | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026